Stock listing
NASDAQ:OLMA Olema Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Olema Pharmaceuticals, Inc.
Follow Olema Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:OLMA
$7.02 USD -0.04 (-0.6%)
Close on Nov 20, 2026
- Day range
- $6.88 – $7.35 USDNov 20, 2026
- Volume
- 1.26M sharesNov 20, 2026
- Market cap
- $615.0M USDAt the close on Nov 20, 2026 · price × 87.61M shares outstanding
- 52-week range
- $6.24 – $36.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10.34M USDMedian day 1.12M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OLMA · Home | $7.02 USD | -0.04 (-0.6%) | 1,256,470 | $7.01 | $7.35 | $6.88 | $7.06 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:OLMA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.02 | -0.04 | -0.6% | $7.01 | $7.35 | $6.88 | 1,256,470 | |
| $7.06 | -0.16 | -2.2% | $7.235 | $7.50 | $7.055 | 1,177,860 | |
| $7.22 | -0.14 | -1.9% | $7.36 | $7.50 | $7.02 | 1,266,249 | |
| $7.36 | -0.20 | -2.6% | $7.48 | $7.73 | $7.08 | 1,524,472 | |
| $7.56 | +0.04 | +0.5% | $7.44 | $7.86 | $7.18 | 1,696,513 | |
| $7.52 | -0.52 | -6.5% | $7.88 | $8.02 | $7.45 | 1,996,916 | |
| $8.04 | +0.77 | +10.6% | $7.29 | $8.25 | $7.07 | 1,819,444 | |
| $7.27 | -0.09 | -1.2% | $7.28 | $7.595 | $7.00 | 935,308 | |
| $7.36 | +0.03 | +0.4% | $7.50 | $7.545 | $7.10 | 1,516,460 | |
| $7.33 | +0.57 | +8.4% | $6.80 | $7.35 | $6.735 | 1,337,270 | |
| $6.76 | -0.78 | -10.3% | $7.49 | $7.52 | $6.71 | 1,703,998 | |
| $7.54 | +0.19 | +2.6% | $7.60 | $7.62 | $7.28 | 1,091,000 | |
| $7.35 | +0.28 | +4.0% | $7.12 | $7.41 | $7.00 | 1,207,346 | |
| $7.07 | +0.07 | +1.0% | $7.00 | $7.13 | $6.71 | 1,118,784 | |
| $7.00 | -0.33 | -4.5% | $7.22 | $7.42 | $6.92 | 751,077 | |
| $7.33 | -0.16 | -2.1% | $7.47 | $7.59 | $7.14 | 1,153,497 | |
| $7.49 | +0.45 | +6.4% | $6.93 | $7.49 | $6.81 | 1,437,507 | |
| $7.04 | +0.42 | +6.3% | $6.62 | $7.13 | $6.49 | 2,190,088 | |
| $6.62 | +0.21 | +3.3% | $6.44 | $6.78 | $6.34 | 1,987,370 | |
| $6.41 | -0.61 | -8.7% | $6.93 | $6.94 | $6.235 | 1,984,600 | |
| $7.02 | -0.03 | -0.4% | $6.96 | $7.10 | $6.83 | 1,064,900 | |
| $7.05 | -0.20 | -2.8% | $7.24 | $7.47 | $7.03 | 1,236,200 | |
| $7.25 | +0.14 | +2.0% | $7.12 | $7.61 | $7.085 | 1,871,500 | |
| $7.11 | +0.53 | +8.1% | $6.68 | $7.255 | $6.68 | 1,272,600 | |
| $6.58 | -0.29 | -4.2% | $6.83 | $6.83 | $6.48 | 1,081,300 | |
| $6.87 | +0.07 | +1.0% | $6.84 | $6.945 | $6.70 | 1,088,400 | |
| $6.80 | -0.22 | -3.1% | $6.92 | $7.15 | $6.61 | 1,845,300 | |
| $7.02 | -0.34 | -4.6% | $7.30 | $7.363 | $6.99 | 2,013,800 | |
| $7.36 | -0.46 | -5.9% | $7.77 | $7.77 | $7.33 | 1,018,700 | |
| $7.82 | 0.00 | 0.0% | $7.77 | $8.00 | $7.725 | 758,200 | |
| $7.82 | -0.12 | -1.5% | $7.87 | $8.21 | $7.56 | 1,400,200 | |
| $7.94 | +0.02 | +0.3% | $7.90 | $8.23 | $7.79 | 819,200 | |
| $7.92 | -0.33 | -4.0% | $8.28 | $8.29 | $7.80 | 1,038,900 | |
| $8.25 | +0.025 | +0.3% | $8.28 | $8.30 | $7.85 | 1,006,100 | |
| $8.225 | -0.045 | -0.5% | $8.39 | $8.52 | $8.10 | 1,071,900 | |
| $8.27 | -0.37 | -4.3% | $8.58 | $8.66 | $8.19 | 1,009,500 | |
| $8.64 | +0.10 | +1.2% | $8.59 | $8.86 | $8.42 | 1,542,800 | |
| $8.54 | -0.07 | -0.8% | $8.60 | $8.73 | $8.46 | 1,079,600 | |
| $8.61 | -0.14 | -1.6% | $8.71 | $8.85 | $8.40 | 979,200 | |
| $8.75 | -0.29 | -3.2% | $9.04 | $9.04 | $8.57 | 1,382,700 | |
| $9.04 | +0.21 | +2.4% | $8.79 | $9.27 | $8.59 | 1,486,100 | |
| $8.83 | -0.81 | -8.4% | $9.64 | $9.64 | $8.70 | 1,642,200 | |
| $9.64 | +0.01 | +0.1% | $9.66 | $9.815 | $9.56 | 1,490,500 | |
| $9.63 | -0.19 | -1.9% | $9.95 | $10.13 | $9.61 | 1,069,600 | |
| $9.82 | -0.08 | -0.8% | $9.88 | $9.93 | $9.75 | 3,061,400 | |
| $9.90 | +0.17 | +1.7% | $9.89 | $10.35 | $9.73 | 1,087,900 | |
| $9.73 | -0.05 | -0.5% | $9.86 | $9.93 | $9.44 | 1,246,300 | |
| $9.78 | -0.51 | -5.0% | $10.29 | $10.34 | $9.65 | 1,733,100 | |
| $10.29 | +0.07 | +0.7% | $9.99 | $10.37 | $9.79 | 1,822,800 | |
| $10.22 | -0.47 | -4.4% | $10.79 | $10.86 | $10.18 | 1,013,500 | |
| $10.69 | +0.33 | +3.2% | $10.19 | $10.98 | $10.11 | 1,116,300 | |
| $10.36 | -0.625 | -5.7% | $11.13 | $11.18 | $10.35 | 863,400 | |
| $10.99 | +0.235 | +2.2% | $10.61 | $11.06 | $10.46 | 736,700 | |
| $10.75 | +0.02 | +0.2% | $10.61 | $10.85 | $10.57 | 505,300 | |
| $10.73 | -0.10 | -0.9% | $10.71 | $10.98 | $10.58 | 773,300 | |
| $10.83 | +0.27 | +2.6% | $10.58 | $11.02 | $10.48 | 866,400 | |
| $10.56 | +0.13 | +1.2% | $10.36 | $10.63 | $10.28 | 766,100 | |
| $10.43 | +0.16 | +1.6% | $10.20 | $10.53 | $10.09 | 937,000 | |
| $10.27 | -0.52 | -4.8% | $10.69 | $10.77 | $10.19 | 740,800 | |
| $10.79 | -0.06 | -0.6% | $10.70 | $10.92 | $10.62 | 383,300 | |
| $10.85 | -0.06 | -0.5% | $10.78 | $10.97 | $10.58 | 471,900 | |
| $10.91 | +0.48 | +4.6% | $10.60 | $11.02 | $10.60 | 799,924 | |
| $10.43 | -0.26 | -2.4% | $10.58 | $10.62 | $10.29 | 727,325 | |
| $10.69 | -0.21 | -1.9% | $10.90 | $11.24 | $10.65 | 748,500 | |
| $10.90 | -0.41 | -3.6% | $11.10 | $11.12 | $10.67 | 1,039,100 |
- Ticker
- NASDAQ:OLMA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 40 slides
Latest news
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Nov 18, 2026
Closed $7.06 (-2.2%) on Nov 18, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
Nov 16, 2026
Closed $7.22 (-1.9%) on Nov 17, 2026
Olema Oncology Announces Corporate Name Change
Nov 12, 2026
Closed $7.52 (-6.5%) on Nov 12, 2026
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
Nov 10, 2026
Closed $7.27 (-1.2%) on Nov 10, 2026
Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
Nov 4, 2026
Closed $6.76 (-10.3%) on Nov 5, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2026
Closed $7.54 (+2.6%) on Nov 4, 2026
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Aug 13, 2026
Closed $10.51 (+0.7%) on Aug 13, 2026
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Aug 10, 2026
Closed $10.43 (-12.6%) on Aug 11, 2026
Olema Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 122 in all · newest Nov 18, 2026 · oldest 2020
- Decks
- 14 decks · latest August 2026
Where Olema Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OLMA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:OLMA | BOATS | United States | USD |
Valuation
Price/book 1.7× against a median of 4.1×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $204.6M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.25
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. · NASDAQ:OLMA | US$615.0M | US$204.6M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.25 |
| Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197 | US$648.7M | US$566.3M | n/a | 37.8× | n/a | 6.8× | −18.6% | 0.0× | n/a |
| Prime Medicine, Inc. · NASDAQ:PRME | US$645.8M | US$695.1M | n/a | 98.4× | n/a | 76.5× | n/a | 13.1× | 2.28 |
| Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT | US$638.7M | US$404.3M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.96 |
| Gubra A/S · OMXCOP:GUBRA | US$638.5M | US$533.6M | 2.6× | 1.4× | 1.7× | 4.2× | 64.1% | 0.2× | n/a |
| Kura Oncology, Inc. · NASDAQ:KURA | US$634.9M | US$152.6M | n/a | 1.9× | n/a | 35.4× | −369.3% | 0.6× | 1.30 |
| Alphamab Oncology · HKEX:9966 | US$628.9M | US$454.4M | n/a | 5.5× | n/a | 2.5× | −20.1% | 0.2× | n/a |
| Iambic Therapeutics, Inc. · NASDAQ:IAM | US$621.4M | US$369.4M | n/a | 39.2× | n/a | n/a | −820.0% | n/a | n/a |
| Janux Therapeutics, Inc. · NASDAQ:JANX | US$616.7M | −US$308.6M | n/a | −13.3× | n/a | 0.7× | −428.7% | 0.0× | 0.95 |
| Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637 | US$608.9M | US$483.3M | n/a | 105× | n/a | 2.9× | n/a | 0.4× | n/a |
| Annexon, Inc. · NASDAQ:ANNX | US$587.7M | US$423.7M | n/a | n/a | n/a | 4.1× | n/a | 0.3× | 1.63 |
| Median of the others | US$631.9M | US$439.0M | 2.6× | 21.6× | 1.7× | 4.1× | −194.7% | 0.2× | 1.63 |
Forecasts
9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 36.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.53 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sean P. Bohen | President and CEO |
| Jason V. O'Byrne | Chief Financial Officer |
| James Wagner | Vice President, Legal Counsel |
| Shawnte M. Mitchell | Chief Legal Officer and Corporate Secretary |
| Courtney O'Konek | Vice President, Corporate Communications |
| Amoli Pandya | Vice President, Corporate Law |
| Angelos Dovletoglou | Senior Vice President, CMC and Supply Chain |
| Ganesh Waghmare | Vice President, Drug Safety and Pharmacovigilance |
| Gopinath Palanisamy | Vice President, Pre-Clinical Pharmacology and Toxicology |
| Julie Dexter | Senior Vice President, People and Culture |
| Kamesh Kuchimanchi | Senior Vice President, Regulatory Affairs |
| Karen Paese | Vice President, Supply Chain |
| Kristin Brosofsky | Vice President, Clinical Operations |
| Margaret Tonda | Vice President, Clinical Science |
| Mark Shilkrut | Senior Vice President, Clinical Development |
| Meghna Chowdary | Senior Vice President, Commercial Strategy and Operations |
| Rachel Wei | Vice President, Biostatistics |
| Radha Iyer | Vice President, Quality Assurance |
| Richard Hernandez | Senior Vice President, Clinical Operations |
| Ronald E. Savage | Vice President, Clinical Pharmacology |
| Yolande Du Toit | Vice President, Medical Affairs |
| David C. Myles | Chief Scientific Officer |
| Naseem Zojwalla | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Angelos Dovletoglou | Senior Vice President, CMC and Supply Chain |
| Courtney O'Konek | Vice President, Corporate Communications |
| David C. Myles | Chief Scientific Officer |
| Ganesh Waghmare | Vice President, Drug Safety and Pharmacovigilance |
| Gopinath Palanisamy | Vice President, Pre-Clinical Pharmacology and Toxicology |
| James Wagner | Vice President, Legal Counsel |
| Jason V. O'Byrne | Chief Financial Officer |
| Julie Dexter | Senior Vice President, People and Culture |
| Kamesh Kuchimanchi | Senior Vice President, Regulatory Affairs |
| Karen Paese | Vice President, Supply Chain |
| Kristin Brosofsky | Vice President, Clinical Operations |
| Margaret Tonda | Vice President, Clinical Science |
| Mark Shilkrut | Senior Vice President, Clinical Development |
| Meghna Chowdary | Senior Vice President, Commercial Strategy and Operations |
| Naseem Zojwalla | Chief Medical Officer |
| Prakash Raman | Director |
| Radha Iyer | Vice President, Quality Assurance |
| Richard Hernandez | Senior Vice President, Clinical Operations |
| Ronald E. Savage | Vice President, Clinical Pharmacology |
| Sean P. Bohen | President and CEO |
| Shawnte M. Mitchell | Chief Legal Officer and Corporate Secretary |
| Yolande Du Toit | Vice President, Medical Affairs |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −1.2% |
| Q2 2026 | Aug 10, 2026 · After close | −12.7% |
| Q1 2026 | May 12, 2026 · Before open | −6.0% |
| Q4 2025 | Mar 2, 2026 | −3.2% |
| Q3 2025 | Nov 10, 2025 · Before open | +4.2% |
| Q2 2025 | Aug 11, 2025 · After close | +16.2% |
| Q1 2025 | May 13, 2025 · After close | −3.9% |
| Q4 2024 | Mar 10, 2025 · Before open | −4.1% |
| Q3 2024 | Nov 12, 2024 · After close | −0.5% |
| Q2 2024 | Aug 6, 2024 · After close | −9.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −9.3% |
| Q4 2023 | Mar 11, 2024 · After close | −6.6% |
| Q3 2023 | Nov 7, 2023 · After close | +3.1% |
| Q2 2023 | Aug 8, 2023 · After close | +12.1% |
| Q1 2023 | May 9, 2023 · After close | −8.7% |
| Q4 2022 | Mar 9, 2023 · After close | +3.5% |
| Q3 2022 | Nov 8, 2022 · After close | −5.1% |
| Q2 2022 | Aug 9, 2022 · After close | −26.7% |
| Q1 2022 | May 9, 2022 · After close | +6.8% |
| Q4 2021 | Feb 28, 2022 · After close | +15.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 40 slides | August 2026 |
| Investor Presentation (January 2026) | Investor deck | 39 slides | Jan 12, 2026 |
| Investor Presentation (October 2025) | Investor deck | 39 slides | Oct 20, 2025 |
| Investor Presentation (August 2025) | Investor deck | 37 slides | Aug 11, 2025 |
| Investor Presentation (March 2025) | Investor deck | 32 slides | Mar 5, 2025 |
| Investor Presentation (January 2025) | Investor deck | 34 slides | Jan 13, 2025 |
| SABCS 2024 | Conference | 18 slides | Dec 10, 2024 |
| Investor Presentation (September 2024) | Investor deck | 30 slides | Sep 27, 2024 |
| ESMO Breast Cancer 2024 | Conference | 19 slides | May 15, 2024 |
| JP Morgan Conference January 2024 | Conference | 28 slides | Jan 8, 2024 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| San Antonio Breast Cancer Symposium (SABCS) 2023 | Conference | 32 slides | Dec 6, 2023 |
| ESMO 2023 | Conference | 27 slides | Oct 23, 2023 |
| Investor Presentation (May 2023) | Investor deck | 37 slides | May 11, 2023 |
| Investor Presentation (November 2022) | Investor deck | 36 slides | November 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$218.5M raised · US$19 a share · TD Cowen +5 Dealers: TD Cowen (lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead), H.C. Wainwright & Co. (co-lead) | Nov 20, 2025 |
| Private placement of common stock and pre-funded warrants Announced: about US$250M · US$9.08 a share · Jefferies +6 Dealers: Jefferies (lead), J.P. Morgan, Goldman Sachs & Co. LLC, Citigroup, LifeSci Capital, Oppenheimer & Co., H.C. Wainwright & Co. Buyers: Adage Capital Partners LP; Bain Capital Life Sciences; BVF Partners L.P.; Driehaus Capital Management; Janus Henderson Investors; Paradigm BioCapital Advisors; Wellington Management; Woodline Partners LP Use of proceeds: Fund the OPERA-02 trial, the Phase 1/2 study of OP-3136, the ongoing Phase 3 OPERA-01 trial, working capital and general corporate purposes | Dec 2, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Olema Pharmaceuticals, Inc. Priced at US$19.00 a share on Nov 18, 2020.
- Price
- US$19.00 a share
- Shares offered
- 11,000,000 shares of common stock
- Offering size
- US$209 million
- Underwriters' option
- Up to 1,650,000 more shares
- Listing
- OLMA on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Jefferies, Cowen, Canaccord Genuity · In the order on the cover
- Shares delivered
- On or about Nov 23, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 21, 2020 |
| Filed publicly | Oct 30, 2020 |
| Amended once | Nov 16, 2020 |
| Shares registered with an exchange | Nov 17, 2020 |
| Declared effective by the SEC | Nov 18, 2020 |
| Final prospectus, with the price | Nov 19, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 19, 2020 |
| EFFECT · Notice that a registration is effective | Nov 18, 2020 |
| S-1MEF · Registration of more shares for the same offering | Nov 18, 2020 |
| CERT · Exchange's certificate of listing | Nov 18, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 17, 2020 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| S-1/A · Registration statement, amended | Nov 16, 2020 |
| UPLOAD · Letter from the SEC | Nov 4, 2020 |
All 15 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Oct 30, 2020 |
| DRSLTR · Letter to the SEC with a draft | Oct 23, 2020 |
| DRS/A · Draft registration statement, amended | Oct 23, 2020 |
| UPLOAD · Letter from the SEC | Oct 16, 2020 |
| DRS · Draft registration statement | Sep 21, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 19, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 393.0K | 377.0K | 1.66M | 1.66M | 11.0K | 9.03K | 8.24K | |
| Gross profit | -393.0K | -377.0K | -1.66M | -1.66M | -11.0K | -9.03K | -8.24K | |
| Research and development | 157.7M | 124.5M | 86.1M | 82.3M | 51.1M | 13.7M | 3.92M | 1.69M |
| Selling, general and administrative | 21.0M | 17.7M | 18.8M | 24.7M | 20.4M | 7.82M | 403.0K | 386.0K |
| Operating income | -178.7M | -142.3M | -105.0M | -107.0M | -71.5M | -21.5M | -4.32M | -2.08M |
| Depreciation and amortization | 490.0K | 393.0K | 377.0K | 357.0K | 163.0K | 11.0K | 9.00K | 8.00K |
| EBITDA | -178.2M | -141.9M | -104.6M | -106.6M | -71.3M | -21.5M | -4.31M | -2.07M |
| Interest expense | 357.0K | 232.0K | 653.0K | 0 | 28.0K | |||
| Income before tax | -162.4M | -129.5M | -96.7M | -104.8M | -71.1M | -22.1M | -4.32M | -2.20M |
| Income tax | 3.00K | 2.00K | 2.00K | 1.00K | -210.0K | 642.0K | -155.9K | -90.0K |
| Net income | -162.5M | -129.5M | -96.7M | -104.8M | -71.1M | -22.1M | -4.32M | -2.20M |
| Earnings per share, basic | -1.87 | -2.20 | -2.14 | -2.62 | -1.80 | -3.42 | -1.66 | -0.16 |
| Earnings per share, diluted | -1.87 | -2.20 | -2.14 | -2.62 | -1.80 | -3.42 | -1.66 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 48.3M | 139.5M | 68.5M | 23.7M | 13.8M | 338.5M | 68.0K | 3.15M |
| Short-term investments | 457.1M | 294.6M | 193.3M | 180.7M | 273.4M | 0 | ||
| Receivables | 4.06M | 2.12M | 673.0K | 319.0K | 130.0K | |||
| Inventory | -4.02M | -319.0K | -353.0K | |||||
| Current assets | 515.5M | 438.5M | 266.5M | 208.9M | 290.7M | 342.1M | 103.0K | 3.24M |
| Property, plant and equipment | 274.0K | 746.0K | 968.0K | 1.48M | 1.47M | 75.0K | 26.0K | 26.0K |
| Total assets | 533.4M | 451.0M | 276.9M | 215.6M | 295.9M | 342.7M | 132.0K | 3.27M |
| Accounts payable | 9.25M | 4.46M | 2.70M | 374.0K | 23.0K | 719.0K | 935.0K | 116.0K |
| Current liabilities | 51.8M | 41.8M | 21.6M | 16.5M | 9.02M | 4.58M | 1.38M | 201.0K |
| Long-term debt | 3.00M | |||||||
| Total debt | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M | |||
| Total liabilities | 54.9M | 42.0M | 23.1M | 18.1M | 11.4M | 4.58M | 10.7M | 9.55M |
| Shareholders' equity | 478.6M | 409.0M | 253.9M | 197.5M | 284.6M | 338.1M | -10.6M | -6.28M |
| Shares outstanding | 81.4M | 74.3M | 55.0M | 40.3M | 39.8M | 39.3M | 40.3M | 14.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -146.7M | -104.4M | -83.7M | -82.1M | -50.7M | -19.9M | -3.08M | -2.18M |
| Capital spending | 0 | -159.0K | 0 | -363.0K | -1.57M | -56.0K | -56.0K | -56.0K |
| Free cash flow | -146.7M | -104.5M | -83.7M | -82.4M | -52.3M | -19.9M | -3.08M | -2.18M |
| Cash from investing | -155.8M | -93.5M | -4.85M | 91.5M | -275.4M | -56.0K | -56.0K | -56.0K |
| Cash from financing | 211.3M | 268.8M | 133.4M | 476.0K | 1.39M | 358.4M | 358.4M | 5.25M |
| Dividends paid | -3.09M | |||||||
| Share buybacks | 1.03M | 476.0K | 1.39M | -2.29M | 0 | 0 | ||
| Change in cash | -91.2M | 70.9M | 44.8M | 9.89M | -324.7M | 338.5M | -3.08M | 3.08M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 8-K · Current report | May 1, 2026 | Material contract | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 29, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 20, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Mar 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 12, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 13, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Jan 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| S-3ASR · Registration statement | Dec 11, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 19, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 19, 2025 | Offer document | SEC |
| S-3MEF | Nov 18, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Nov 18, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 16, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | May 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 28, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 16, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jan 16, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Jan 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 15, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 13, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jan 13, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 13, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 8-K · Current report | Jan 10, 2025 | Financing | SEC |
| UPLOAD · Letter from the SEC | Jan 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 8, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jan 6, 2025 | Offer document | SEC |
| S-3 · Registration statement | Jan 3, 2025 | Offer document | SEC |
| 4/A · Change in ownership, amended | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| D | Dec 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Dec 11, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 2, 2024 | Material contract | SEC |
| 4/A · Change in ownership, amended | Nov 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Sep 27, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
This page holds 200 of 566 filings. Open Filings
Cap table
Built by 6ix from Olema Pharmaceuticals, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 87,606,263
- Fully diluted
- 87,606,263
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 87,606,263 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 87,606,263 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bihua Chen Other companies: BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Biomea Fusion, Inc. (Director · Since at least Apr 15, 2021); Erasca, Inc. (Director · Jul 15, 2021 – Jun 22, 2023 · Past); Monte Rosa Therapeutics, Inc. (Director · Jun 23, 2021 – Jun 23, 2021 · Past); Verve Therapeutics Inc (Director · Jun 16, 2021 – Jun 21, 2021 · Past); Rain Oncology Inc (Director · Apr 22, 2021 – Apr 27, 2021 · Past); Design Therapeutics, Inc. (Director · Mar 25, 2021 – Mar 25, 2021 · Past); Prometheus Biosciences Inc (Director · Mar 11, 2021 – Mar 11, 2021 · Past); BioAtla, Inc. (Director · Dec 15, 2020 – Dec 18, 2020 · Past); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); MoonLake Immunotherapeutics (CEO and Chairman, Director · Oct 19, 2020 – Oct 22, 2020 · Past); Akouos Inc (Director · Jun 25, 2020 – Jun 30, 2020 · Past); Avidity Biosciences, Inc (Director · Jun 11, 2020 – Jun 16, 2020 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Aug 12, 2019 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Oct 31, 2018 · Past); Constellation Pharmaceuticals Inc (Director · Jul 18, 2018 – Jul 18, 2018 · Past); Kezar Life Sciences, Inc. (Director · Jun 20, 2018 – Jun 25, 2018 · Past); Kiniksa Pharmaceuticals International, plc (Director · May 23, 2018 – May 29, 2018 · Past); Apellis Pharmaceuticals, Inc. (Director · Nov 8, 2017 – Nov 13, 2017 · Past); Kineta Inc. (Director · Nov 3, 2016 – Dec 14, 2017 · Past); Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 1, 2016 · Past); Cellectar Biosciences, Inc. (Director · Aug 15, 2014 – Aug 15, 2014 · Past) | Director · Nov 18, 2020 – Nov 23, 2020 · Past |
| Ian T. Clark Other companies: Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); BioMarin Pharmaceutical Inc. (Chair of the Board, · Since at least Aug 1, 2025); GoodRx Holdings, Inc. (Director · Since at least Jul 8, 2024); Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 7, 2024); Guardant Health, Inc. (Director · Since at least Oct 3, 2018); Corvus Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2017); Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Kite Pharma Inc (Director · Jan 3, 2017 – Oct 3, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Dec 30, 2016 – May 20, 2022 · Past); Terravia Holdings Inc (Director · May 26, 2011 – May 22, 2017 · Past); Dendreon Corp (Director · Oct 7, 2009 – Aug 20, 2010 · Past); Genentech Inc (EVP-COMMERCIAL · Sep 20, 2006 – Mar 26, 2009 · Past) | Director · Since at least Aug 12, 2020 |
| Scott Garland Other companies: Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Jan 7, 2026); LB Pharmaceuticals Inc (Chairman of the Board, LB Pharmaceuticals · Since at least Sep 10, 2025); ALX Oncology Holdings Inc. (Chairman · Since at least Nov 28, 2022); Day One Biopharmaceuticals Inc (Director · Since at least Aug 16, 2021); Calithera Biosciences, Inc. (Director · Jul 10, 2020 – Jun 1, 2022 · Past); Portola Pharmaceuticals Inc (President and CEO, Director · Oct 8, 2018 – Jul 2, 2020 · Past); Karyopharm Therapeutics Inc. (Director · Nov 3, 2014 – Jun 6, 2019 · Past); Relypsa Inc (SVP & Chief Commercial Officer · Oct 31, 2014 – Sep 1, 2016 · Past); Exelixis, Inc. (EVP & Chief Commerical Officer · Oct 20, 2011 – Sep 18, 2013 · Past) | Director · Since at least Oct 16, 2023 |
| Mark N Lampert Other companies: Immunic, Inc. (Director · Since at least Feb 17, 2026); Kymera Therapeutics, Inc. (Director · Since at least Jan 11, 2023); MoonLake Immunotherapeutics (Director · Since at least Apr 5, 2022); Rain Oncology Inc (Director · Nov 8, 2022 – Jan 25, 2024 · Past); CTi Biopharma Corp (Director · Aug 9, 2022 – Jun 26, 2023 · Past) | Director · Since at least Jun 10, 2022 |
| Sandra J. Horning Other companies: Revolution Medicines, Inc. (Director · Since at least Nov 9, 2023); Moderna, Inc. (Director · Since at least Apr 29, 2020); Gilead Sciences, Inc. (Director · Since at least Jan 28, 2020); EQRx Inc (Director · Dec 17, 2021 – Nov 9, 2023 · Past); Foundation Medicine Inc (Director · Apr 7, 2015 – Apr 7, 2015 · Past) | Director · Since at least Nov 18, 2020 |
| Cynthia M. Butitta Other companies: Autolus Therapeutics plc (Chair of the Compensation Committee, Member of the Audit Committee · Since at least Mar 18, 2026); Century Therapeutics, Inc. (Director · Since at least Jun 17, 2021); UroGen Pharma Ltd. (of the Audit Committee · Since at least Jan 1, 2019); Kite Pharma Inc (Chief Operating Officer · Jun 19, 2014 – Oct 3, 2017 · Past) | Director · Since at least Aug 12, 2020 |
| Frank McCormick Other companies: BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); BridgeBio Pharma, Inc. (Director · Since at least Jun 27, 2019); Aduro Biotech Inc (Director · Apr 14, 2015 – Jun 6, 2018 · Past); Exelixis, Inc. (Director · May 2, 2006 – Dec 6, 2013 · Past) | Director · Sep 18, 2020 – Nov 23, 2020 · Past |
| John Moriarty Other companies: Kardigan, Inc. (Chief Legal Officer and Corporate Secretary · Since at least Jun 17, 2026); Avidity Biosciences, Inc (Chief Legal Officer · Since at least Aug 1, 2024); Portola Pharmaceuticals Inc (EVP, General Counsel · Mar 12, 2018 – Jul 2, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & General Counsel · Dec 10, 2012 – Feb 6, 2018 · Past) | EVP, Ch. Legal Officer & Sec. · Sep 19, 2020 – Feb 1, 2023 · Past |
| G Walmsley Graham Other companies: Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); LifeSci Acquisition II Corp (Director · Nov 20, 2020 – Nov 20, 2020 · Past); ALX Oncology Holdings Inc. (Director · Jul 16, 2020 – Jun 11, 2021 · Past) | Director · Since at least Jun 1, 2020 |
| Gorjan Hrustanovic Other companies: Kymera Therapeutics, Inc. (Director · Since at least Jun 16, 2021); Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past) | Director · Since at least Nov 18, 2020 |
All 44 people
| Person | Seat |
|---|---|
| Jason V. O'Byrne Other companies: Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Since at least Oct 2, 2024); Caribou Biosciences, Inc. (Chief Financial Officer · Jul 22, 2021 – Feb 20, 2024 · Past) | Chief Financial Officer · Since at least Aug 11, 2026 |
| Shawnte M. Mitchell Other companies: Zogenix Inc (EVP, GC & Secretary · Apr 20, 2020 – Mar 7, 2022 · Past); Aptevo Therapeutics Inc. (SVP, GC and Corporate Affairs · Aug 1, 2018 – Feb 18, 2020 · Past) | Chief Legal Officer and Corporate Secretary · Since at least Feb 18, 2025 |
| Yi Larson Other companies: RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Turning Point Therapeutics Inc (EVP & Chief Financial Officer · Aug 26, 2019 – Feb 8, 2021 · Past) | Director · Since at least Apr 5, 2021 |
| Andrew Rappaport Other companies: Atheros Communications Inc (Director · Feb 7, 2006 – May 24, 2011 · Past) | Director · Since at least Sep 18, 2020 |
| Kinney Horn Other companies: Immunome, Inc. (CHIEF BUSINESS OFFICER · Since at least Feb 12, 2024) | Chief Business Officer · Jun 10, 2020 – Feb 1, 2023 · Past |
| Prakash Raman Other companies: Black Diamond Therapeutics, Inc. (CEO of InduPro, Inc. · Since at least Apr 10, 2024) | Director · Since at least Apr 28, 2026 |
| Shane William Charles Kovacs Other companies: PTC Therapeutics, Inc. (Chief Financial Officer · Sep 26, 2016 – May 9, 2017 · Past) | CH. OPERATING & FINANCIAL OFF. · Since at least Jun 15, 2020 |
| Amoli Pandya | Vice President, Corporate Law · Since at least Nov 13, 2026 |
| Angelos Dovletoglou | Senior Vice President, CMC and Supply Chain · Since at least Nov 5, 2026 |
| Brad Lanoue | Vice President, Market Access · Nov 4, 2026 – Nov 13, 2026 · Past |
| Courtney O'Konek | Vice President, Corporate Communications · Since at least Nov 3, 2026 |
| Cyrus Harmon | Director · Since at least Jun 15, 2020 |
| David C. Myles | Chief Scientific Officer · Since at least Jun 15, 2020 |
| Ganesh Waghmare | Vice President, Drug Safety and Pharmacovigilance · Since at least Nov 5, 2026 |
| Gopinath Palanisamy | Vice President, Pre-Clinical Pharmacology and Toxicology · Since at least Apr 25, 2025 |
| James Wagner | Vice President, Legal Counsel · Since at least Nov 5, 2026 |
| Julie Dexter | Senior Vice President, People and Culture · Since at least Nov 5, 2026 |
| Kamesh Kuchimanchi | Senior Vice President, Regulatory Affairs · Since at least Nov 5, 2026 |
| Karen Paese | Vice President, Supply Chain · Since at least Nov 5, 2026 |
| Kate Swearingen | Vice President, Program Management · Nov 4, 2026 – Nov 13, 2026 · Past |
| Kristin Brosofsky | Vice President, Clinical Operations · Since at least Nov 5, 2026 |
| Margaret Tonda | Vice President, Clinical Science · Since at least Nov 5, 2026 |
| Mark Shilkrut | Senior Vice President, Clinical Development · Since at least Nov 5, 2026 |
| Meghna Chowdary | Senior Vice President, Commercial Strategy and Operations · Since at least Nov 5, 2026 |
| Naseem Zojwalla | Chief Medical Officer · Since at least Jan 31, 2022 |
| Peter J Kushner | CHIEF SCIENTIFIC OFFICER · Jun 15, 2020 – Feb 1, 2022 · Past |
| Rachel Wei | Vice President, Biostatistics · Since at least Nov 13, 2026 |
| Radha Iyer | Vice President, Quality Assurance · Since at least Nov 5, 2026 |
| Richard Hernandez | Senior Vice President, Clinical Operations · Since at least Nov 5, 2026 |
| Ronald E. Savage | Vice President, Clinical Pharmacology · Since at least Nov 5, 2026 |
| Sasha Austin | Vice President, Finance and Controller · Nov 4, 2026 – Nov 13, 2026 · Past |
| Sasha Lu Austin | VP of Finance and Controller · Since at least Jan 30, 2026 |
| Sean P. Bohen | President and CEO · Since at least Sep 19, 2020 |
| Yolande Du Toit | Vice President, Medical Affairs · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Olema Pharmaceuticals, Inc.